PresentationPresentation Results of the Pivotal STORM Study (Part 2): Deep and Durable Responses with Oral Selinexor plus Low Dose Dexamethasone in Patients with Penta-Exposed and Triple Class Refractory MM PDF (977.89 KB) Read MorePresentation Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome(SDd) in Patients with Multiple Myeloma Previously Treated with PIs and IMiDs: Results of Phase 1b/2 Study of SDd PDF (521.56 KB) Read MorePresentation Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma PDF (1.45 MB) Read MorePresentation Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b SADAL Study PDF (1.36 MB) Read MorePresentation Selinexor, a First-in-Class XP01 Inhibitor, is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes (MDS) Refractory to Hypomethylating Agents PDF (1.32 MB) Read MorePresentation Phase I Trial of the Selective Inhibitor of Nuclear Export, SELINEXOR, in Relapsed Childhood Leukemia PDF (2.62 MB) Read MorePresentation Final Results from a Phase I Trial Combining Selinexor with High-dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML) PDF (333.28 KB) Read MorePresentation Efficacy of Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma: Results of the Pivotal STORM Part II Study PDF (1.97 MB) Read MorePresentation Selinexor combined with low dose bortezomib and dexamethasone (SVd) induces a high response rate in patients with relapsed or refractory multiple myeloma (MM) PDF (718.17 KB) Read MorePresentation A Phase 1b study using the combination of selinexor, daratumumab, and dexamethasone in multiple myeloma patients previously exposed to proteasome inhibitors and immunomodulatory drugs PDF (556.14 KB) Read More1 2 3 … 15 Next